(-0.48%) 5 047.32 points
(-1.01%) 38 072 points
(-0.69%) 15 605 points
(1.06%) $83.69
(-2.66%) $1.609
(0.31%) $2 345.60
(0.28%) $27.42
(1.05%) $925.40
(-0.28%) $0.932
(-0.18%) $10.96
(-0.43%) $0.799
(-0.08%) $92.24
Live Chart Being Loaded With Signals
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally...
Stats | |
---|---|
Today's Volume | 58 934.00 |
Average Volume | 38 985.00 |
Market Cap | 514.12M |
EPS | €0 ( 2024-04-24 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 262.00 |
ATR14 | €0.0510 (0.18%) |
Volume Correlation
Pharma Mar, S.A. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pharma Mar, S.A. Correlation - Currency/Commodity
Pharma Mar, S.A. Financials
Annual | 2023 |
Revenue: | €158.15M |
Gross Profit: | €144.86M (91.60 %) |
EPS: | €0.0635 |
Q4 | 2023 |
Revenue: | €40.51M |
Gross Profit: | €38.06M (93.95 %) |
EPS: | €-0.390 |
Q3 | 2023 |
Revenue: | €37.45M |
Gross Profit: | €34.31M (91.60 %) |
EPS: | €0.0846 |
Q2 | 2023 |
Revenue: | €46.21M |
Gross Profit: | €44.32M (95.91 %) |
EPS: | €0.280 |
Financial Reports:
No articles found.
Pharma Mar, S.A.
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators